JC
Therapeutic Areas
MAIA Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ateganosine (THIO) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 |
| Second-generation telomere targeting agents | Cancer | Pre-clinical/Research |
Leadership Team at MAIA Biotechnology
VV
Vlad Vitoc, MD, MBA
Chief Executive Officer and Chairman
SM
Sergei M. Gryaznov, PhD
Chief Scientific Officer